California biotech Kali Therapeutics secured $180 million in near-term payments from Sanofi for rights to a T-cell engager (TCE) targeting autoimmune diseases5
This represents Kali Therapeutics' first major pharma partnership5
The deal is part of Sanofi's broader strategy to strengthen its T-cell engager portfolio, which includes acquiring Amunix Pharmaceuticals for $1 billion upfront and licensing TCE assets to Vir Biotechnology7
T-cell engagers are immunotherapy agents designed to activate T cells to target disease, with applications in oncology, infectious diseases, and autoimmune conditions245
Sources:
2. https://synapse.patsnap.com/article/vir-biotechnology-expands-strategy-with-sanofi-license-for-clinical-stage-t-cell-engagers
4. https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx
5. https://pharmaphorum.com/news/sanofi-pays-180m-rights-kali-autoimmune-drug
7. https://www.fiercebiotech.com/biotech/sanofi-gambles-1b-upfront-preclinical-oncology-biotech-bagging-amunix-for-its-pipeline-t